What is William Blair's Estimate for ResMed FY2025 Earnings?

ResMed Inc. (NYSE:RMD - Free Report) - Stock analysts at William Blair increased their FY2025 earnings per share estimates for shares of ResMed in a research report issued to clients and investors on Monday, February 3rd. William Blair analyst M. Andrew now forecasts that the medical equipment provider will post earnings of $9.40 per share for the year, up from their prior estimate of $9.30. The consensus estimate for ResMed's current full-year earnings is $9.44 per share. William Blair also issued estimates for ResMed's Q1 2026 earnings at $2.66 EPS, Q2 2026 earnings at $2.80 EPS, Q3 2026 earnings at $2.55 EPS and Q4 2026 earnings at $2.67 EPS.

Several other equities analysts have also weighed in on RMD. StockNews.com upgraded shares of ResMed from a "hold" rating to a "buy" rating in a research report on Tuesday, October 15th. Stifel Nicolaus initiated coverage on ResMed in a research report on Friday, December 13th. They set a "hold" rating and a $250.00 target price on the stock. JPMorgan Chase & Co. increased their price target on ResMed from $270.00 to $286.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. Piper Sandler boosted their price objective on ResMed from $252.00 to $260.00 and gave the stock a "neutral" rating in a report on Friday, January 31st. Finally, KeyCorp lifted their target price on shares of ResMed from $266.00 to $280.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. One analyst has rated the stock with a sell rating, six have issued a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $244.73.

ResMed Price Performance

Shares of RMD traded down $0.34 during midday trading on Wednesday, reaching $236.84. The stock had a trading volume of 830,561 shares, compared to its average volume of 1,059,213. The firm's 50 day moving average price is $239.18 and its 200-day moving average price is $237.39. The company has a market capitalization of $34.78 billion, a P/E ratio of 27.96, a P/E/G ratio of 1.57 and a beta of 0.70. ResMed has a 52 week low of $170.56 and a 52 week high of $263.05. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29.

ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping analysts' consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%.

Institutional Trading of ResMed

A number of hedge funds have recently modified their holdings of the company. State Street Corp lifted its position in ResMed by 1.9% in the third quarter. State Street Corp now owns 6,261,633 shares of the medical equipment provider's stock worth $1,528,590,000 after purchasing an additional 116,918 shares during the period. Geode Capital Management LLC raised its stake in shares of ResMed by 10.9% in the 3rd quarter. Geode Capital Management LLC now owns 3,858,814 shares of the medical equipment provider's stock valued at $939,114,000 after buying an additional 380,383 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of ResMed by 3.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 957,020 shares of the medical equipment provider's stock worth $218,861,000 after acquiring an additional 32,973 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of ResMed by 0.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 742,411 shares of the medical equipment provider's stock valued at $181,237,000 after acquiring an additional 2,406 shares in the last quarter. Finally, Los Angeles Capital Management LLC increased its stake in ResMed by 60.0% in the fourth quarter. Los Angeles Capital Management LLC now owns 668,908 shares of the medical equipment provider's stock valued at $152,973,000 after acquiring an additional 250,746 shares during the period. Institutional investors own 54.98% of the company's stock.

Insider Activity

In related news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $245.65, for a total value of $491,300.00. Following the completion of the sale, the director now owns 81,218 shares in the company, valued at approximately $19,951,201.70. This trade represents a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Justin Leong sold 6,160 shares of the business's stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $243.09, for a total value of $1,497,434.40. Following the transaction, the insider now owns 21,718 shares in the company, valued at $5,279,428.62. This represents a 22.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 11,094 shares of company stock valued at $2,704,941. 0.71% of the stock is owned by insiders.

ResMed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date is Thursday, February 13th. ResMed's dividend payout ratio (DPR) is 25.03%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.